Urinary metabolites of DX-8951, a novel camptothecin analog, in rats and humans

Arzneimittel-Forschung/Drug Research

Volumn 51, Issue 3, 2001, Pages 253-257

  Atsumi, R ^a   Oguma, T ^a   Yoshioka, N ^a   Konno, T ^a   Okazaki, O ^a   Fujimaki, Y ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

Camptothecin, derivative; CAS 171335 80 1; Cytostatics; DX 8951, human, metabolites, rat; Exatecan

Indexed keywords

3 HYDROXYEXATECAN; 4 HYDROXYMETHYLEXATECAN; CAMPTOTHECIN DERIVATIVE; D 61 7153; D 91 2373; DRUG METABOLITE; EXATECAN; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ARTICLE; CASE REPORT; CLINICAL TRIAL; DRUG DETERMINATION; DRUG IDENTIFICATION; DRUG STRUCTURE; DRUG URINE LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; ION EXCHANGE CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHASE 1 CLINICAL TRIAL; RAT; STRUCTURE ANALYSIS;

EID: 0035076319     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1300032     Document Type: Article

References (4)

1. A new water-solube camptothecin derivative, DX-8951f, exhibits potents antitumor activity against human tumors in vitro and in vivo
2. DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant
3. Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice
4. Phase I study and clinical pharmacology of DX-8951f, a new camptothecin derivative, infused over 30 minutes every 3 weeks